{"disease":{"id":"renal-pelvic-carcinoma","name":"renal pelvic carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06652022","title":"Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs","phase":"NA","overall_status":"RECRUITING","enrollment_count":102,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT06598761","title":"Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT07233252","title":"Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}